MedTrace Logo

China Stroke Secondary Prevention Trial

NCT01317849 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-08-20

No results posted yet for this study

Summary

The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in China to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke events and other combined incidence of recurrent vascular events and vascular death.

Conditions

  • Stroke
  • Transient Ischemic Attack

Interventions

DRUG

Folic Acid

0.8mg

DRUG

Vitamin B6

10mg

DRUG

Vitamin B12

500ug

DRUG

placebo

0.8 mg

DRUG

placebo

10mg

DRUG

placebo

500ug

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Gang Zhao, MD · the Department of Neurology , Xijing Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01317849 on ClinicalTrials.gov